Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02263820 · ClinicalTrials.gov registry record
Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography
A clinical trial, sponsored by Sapere Bio.
- Completed
- Registry status
- 185
- Enrollment target
NCT02263820: Completed study, sponsored by Sapere Bio.
NCT02263820 is a clinical trial that has completed, run by Sapere Bio. The registered enrollment target is 185 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02263820 has completed, sponsored by Sapere Bio.
- COMPLETED
- Registry status
- 185 participants
- Enrollment target
Study Summary
Contrast-induced acute kidney injury (CI-AKI) has been recognized as the third most common cause of hospital acquired AKI, after hypotension-associated hypo-perfusion and post-operative AKI. The development of CI-AKI after cardiac catheterization is associated with a significant increase in both short-term and long-term mortality and morbidities, as well as an increase in length of stay and cost. The only marker of renal function that has predictive ability is creatinine and it has significant limitations in identifying patients who will develop AKI. Therefore, a diagnostic test for predicting CI-AKI risk would have widespread clinical utility. The primary purpose of this study is to measure the association between baseline expression of senescence markers in blood using SenesceTest and the occurrence of CI-AKI post cardiac catheterization.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-12 |
What the finished NCT02263820 record still lists
NCT02263820 is an observational study that tracks outcomes without assigning an intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02263820 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02263820 about?
NCT02263820 is a clinical study titled "Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography". Contrast-induced acute kidney injury (CI-AKI) has been recognized as the third most common cause of hospital acquired AKI, after hypotension-associated hypo-perfusion and post-operative AKI. The development of CI-AKI after cardiac catheterization is associated with a significant increase in both sho...
What is the current status of trial NCT02263820?
This trial is currently completed. The enrollment target is 185 participants. The study started on 2015-01. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT02263820?
This trial is sponsored by Sapere Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia